Patent-Protected Botanical Drug Platform

Protect and renew the aging immune-hematopoietic reserve.

A two-component botanical drug candidate targeting immunosenescence and metabolic-mitochondrial decline. One component protects surviving cells; the other renews mitochondrial and stem-cell reserve. Advancing through the FDA Botanical Drug pathway.

Request one-pager See the mechanism ↓
2
Component botanical formulation
6
Validated mechanisms of action
1,000+
Preclinical subjects, related indication
IND
FDA Botanical Drug pathway
The Problem

Immunosenescence is the defining challenge no single product addresses.

A 1.5 billion-person gap

Progressive loss of immune competence after age 55 drives multi-morbidity, infectious susceptibility, and accelerated biological aging — affecting more than 1.5 billion people globally.

No mechanistic specificity

No approved therapeutic simultaneously addresses the root mechanisms: oxidative stress driving aging, hematopoietic decline, chronic inflammaging, and failure of adaptive hormetic defenses.

Generic supplements dominate

NMN, resveratrol, and NAD+ products lead the category but lack patent protection, mechanistic precision, or validated clinical rationale.

A $42B market without a category leader

The healthspan economy is enormous and still searching for its defining, defensible product.

The Platform

Protect. Renew. One synergistic composition.

One component protects the aging cell — antioxidant, anti-inflammatory, reserve-sparing. The other renews it — mitochondrial biogenesis, senescence delay. The specific combination, not any single known ingredient, is the inventive core.

PROTECT · CONFIRMED
Oxidative-stress reduction (Nrf2/ARE)

Lowers ROS, MDA, AGEs; raises glutathione — reducing the oxidative damage that drives immunological aging.

MDA, glutathione, AGEs
PROTECT · CONFIRMED
Anti-inflammaging

Lowers IL-6, IL-8, IL-1β — suppressing the chronic low-grade inflammation that accelerates immune decline.

Serum IL-6, IL-8, IL-1β
PROTECT · CONFIRMED
Immune-reserve correction

Normalizes immune indices under suppression — sparing and restoring the body's residual immune competence.

Immune indices, hematopoietic recovery
RENEW · REASONED
Mitochondrial biogenesis → senescence delay

Activates PGC-1α / SIRT1 / TFAM axis — restores mitochondrial mass, membrane potential, and ATP under oxidative stress.

PGC-1α, mitochondrial mass, ATP
RENEW · REASONED
HSC reserve maintenance (PARP-1)

Protects quiescent hematopoietic stem cells from oxidative attrition via DNA-repair (PARP-1) — preserving the long-term immune-hematopoietic reserve.

HSC quiescence, PARP-1, DNA integrity
SYNERGY · HYPOTHESIS
Combination convergence

Primary base protects existing mitochondria from oxidative damage; second component builds new ones. Supra-additive synergy pending combination study.

Colby synergy validation
IP & Scientific Validation

Patent filed. Regulatory pathway de-risked.

Patent

IP protection covers the specific two-component formulation, ratio, preparation method, and oral form. Defensibility rests on the specific combination — not any single publicly-known component.

Preclinical

1,000+ subjects studied in cyclophosphamide myelosuppression models. A 4-group mechanistic study and Colby synergy validation are planned, alongside a D-galactose aging model validation in Phase 1.

Regulatory

FDA Botanical Drug Guidance (2016) pathway toward IND for the aging indication. Free of cyanogenic glycosides; ICH Q1A(R2) 12-month stability claimed.

Regulatory de-risking

Drug pathwayFDA Botanical Drug → IND
Patent statusFiling in preparation
StabilityICH Q1A(R2), 12 mo
Safety profileNo cyanogenic glycosides
Team

Operators and scientists, not first-time founders.

Giorgi Chiteishvili
Giorgi Chiteishvili
CEO

Serial entrepreneur with 15 years in banking and venture-building. Concurrently CEO of Immune-G Ltd. and DetentionPro.

Vladimir Kharabadze
Vladimir Kharabadze
Co-Founder · Preclinical Lead

Healthcare specialist leading preclinical research and formulation development.

Giorgi Karabaki
Giorgi Karabaki
Co-Founder · Botanical Research

Focused on botanical pharmacology and hematopoietic research underlying the platform's mechanism work.

Platform optionality — Immune-S. A sister program applying the same primary botanical base with a different second component for post-chemotherapy myelosuppression — a distinct FDA Botanical Drug indication with its own composition and IP. Shared base means shared groundwork; each product carries its own second-component and formulation profile.

Building the category-defining geroprotector.

Patent filed. FDA Botanical Drug pathway. We're sharing materials with investors who think about aging biology and execution-stage de-risking the same way we do.

Request one-pager